Nigeria’s pharmaceutical manufacturers are finally seeing a silver lining in their balance sheets, but for the average patient at the pharmacy counter, the relief remains invisible. While federal ...

Collegium Pharmaceutical (NASDAQ:COLL) highlighted a “record-breaking” 2025 and outlined its 2026 outlook at the Barclays ...

Verrica Pharmaceuticals (NASDAQ:VRCA) used its fourth quarter and year-end 2025 corporate update call to highlight what ...

Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize ...

Combining Trinity's high yield and Bristol Myers' defensive dividend growth can enhance both income and total return for ...

Barclays 28th Annual Global Healthcare Conference March 11, 2026 3:30 PM EDTCompany ParticipantsSteven Basta - ...

In Burgess's case, scammers used her debit and credit cards to make 25 fraudulent charges. On her statements, the charges appeared as payments to UCW — University Canada West — an accredited private ...

Whether happening in public or private, biopharma M&A is fiercer than ever. Experts point to patent pressures, herd mentality ...

U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in cash, cash equivalents and short ...

Detailed price information for Okyo Pharma Limited ADR (OKYO-Q) from The Globe and Mail including charting and trades.

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging ...

U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in ...